Bepirovirsen Market Size to Surpass USD 2,116.99 Million by 2035; Growing at a CAGR of 29.6%
Published : 23 Oct 2026
Author : Simone Lamb
What is the Bepirovirsen Market Size?
The global bepirovirsen market size is valued at USD 36.04 million in 2026 which is seen to reach at USD 266.13 million in 2027 and USD 2,116.99 million by 2035; growing at a promising CAGR of 29.6% during the forecast period of 2026-2035. Increasing demand for innovative chronic hepatitis B treatments, advances in antisense oligonucleotide technology, clinical evidence supporting functional cure potential, and regulatory progress are expected to create new commercial opportunities for bepirovirsen.
What is Bepirovirsen Market?
Bepirovirsen market includes bepirovirsen development, commercialization, distribution and application in clinical trials for chronic hepatitis B. Bepirovirsen is an antisense oligonucleotide in development for chronic hepatitis B, which interacts with hepatitis B virus (HBV) RNA to decrease the synthesis of the viral proteins, for example hepatitis B surface antigen (HBsAg), and with hepatitis B surface antigen to attain a functional cure of patients eligible for therapy. The growth of this market is primarily driven by pipeline products development, growing response rates in clinical trials, as well as in-licensing and strategic alliances.
Key Growth Factors
- Growing Need for Functional Cure Options: The limitations of conventional antiviral therapies, which generally suppress viral replication without eliminating the infection, are increasing interest in treatments that may help eligible patients achieve a functional cure.
- Advances in Antisense Oligonucleotide Technology: Progress in RNA-targeting therapeutics is supporting the development of treatments that reduce hepatitis B viral protein production, potentially improving treatment outcomes when combined with existing antiviral therapy.
- Clinical Trial Progress and Regulatory Approvals: Positive Phase III clinical findings and regulatory milestones are strengthening the commercial outlook for bepirovirsen and may encourage greater interest among healthcare providers, pharmaceutical companies, and healthcare payers.
- Improved Diagnosis and Patient Identification: Wider access to hepatitis B screening and quantitative HBsAg testing could help healthcare professionals identify patients who meet treatment eligibility criteria, supporting appropriate prescribing and potential market adoption.
- Increasing Investment in Hepatitis B Therapeutics: Pharmaceutical research and development investment in functional cure strategies is supporting innovation in chronic hepatitis B treatment and creating opportunities for new therapeutic approaches.
Bepirovirsen Market Segmentation Outlook
| Market Segment | Dominant Segment | Market Share (2027) | Key Driver |
|---|---|---|---|
| By Baseline HBsAg Level | >100 to ≤1,000 IU/mL | 38% | Patient eligibility and treatment response considerations |
| By HBeAg Status | HBeAg-negative | 84% | High prevalence of HBeAg-negative chronic hepatitis B among eligible patients |
| By End User | Hospital Hepatology and Gastroenterology Centres | 58% | Specialist expertise and access to advanced hepatitis B care |
| By Distribution Channel | Specialty Pharmacies | 48% | Specialized medication handling and patient support services |
U.S. FDA Approval and Its Impact on the Bepirovirsen Market
GSK's Hibsago (bepirovirsen) has received FDA approval for the treatment of chronic hepatitis B, representing the key development in the market of chronic hepatitis B. The Food and Drug Administration (FDA) granted approval for Hibsago on 20 October 2026. It is the first FDA-approved antisense oligonucleotide drug for the treatment of chronic hepatitis B.
The commercial upside that could result from an FDA approval is growth via specialist prescriptions, better access to patients and a standard course of therapy of up to 24 weeks. Potential limitation, however, is that not all patients with chronic hepatitis B are eligible for treatment and that the therapy carries some risks, in particular liver complications and low blood counts.
Ultimately, the commercial expansion will require that potential patients are found, that doctors prescribe the drug, that a cost-effective form of treatment is established, that insurance reimbursements are obtained and that GSK commercializes the product appropriately.
Bepirovirsen Market Regional Outlook
North America is forecast to account for 73.86% of the Bepirovirsen Market in 2027, generating $ 196.56 million in revenue. By 2035, its market share is projected to fall to 46.42%, even as regional revenue increases to $982.80 million. This pattern suggests that North America will continue expanding while other regions capture a larger proportion of global demand.
Established hepatology services, access to diagnostic testing, and specialist management of chronic hepatitis B provide a foundation for market development. The U.S. FDA approved Hibsago (bepirovirsen) on October 20, 2026, for eligible adults without cirrhosis who meet the specified treatment and laboratory criteria. The approval could support commercial adoption in the region, although patient eligibility, reimbursement, pricing, and treatment monitoring will influence uptake.
Europe is projected to record the fastest regional growth in the supplied forecast, with a CAGR of 52.7% between 2027 and 2035. Its market share is expected to rise from 6.76% in 2027 to 25.10% in 2035, while revenue increases from USD 17.99 million to USD 531.32 million. This projected expansion reflects the potential for bepirovirsen to reach eligible patients across multiple national healthcare systems. In March 2026, GSK announced that the European Medicines Agency had accepted its marketing authorisation application for review, supported by Phase III clinical trial results.
Top Countries to Contribute to Bepirovirsen Market by 2035
- United States: The United States is expected to remain a leading contributor to the Bepirovirsen Market through 2035, supported by FDA approval of Hibsago, established hepatology services, and access to advanced hepatitis B treatments.
- Germany: Germany could represent an important European market as access to innovative chronic hepatitis B treatments expands. Adoption will depend on regulatory authorization, reimbursement decisions, specialist recommendations, and the integration of bepirovirsen into established hepatology care pathways.
- United Kingdom: The United Kingdom presents potential growth opportunities through specialist liver-care services and established hepatitis B management programmes. Uptake will depend on regulatory authorization, health technology assessment, NHS reimbursement decisions, and clinical recommendations for eligible patients.
- Japan: Japan is expected to remain a significant national market, supported by its early approval of bepirovirsen and established healthcare infrastructure. Reimbursement arrangements, patient eligibility, and specialist adoption will influence commercial uptake through 2035.
- China: China could become an increasingly important contributor as regulatory access and treatment availability evolve. Its substantial chronic hepatitis B patient population offers potential demand, while affordability, reimbursement, diagnostic capacity, and regulatory authorization will shape the pace of market expansion.
Bepirovirsen Market Segments Covered
By Baseline HBsAg Level
- ≤100 IU/mL
- >100 to ≤1,000 IU/mL
- >1,000 to ≤3,000 IU/mL
By HBeAg Status
- HBeAg-Negative
- HBeAg-Positive
By End User
- Hospital Hepatology & Gastroenterology Centers
- Specialty Clinics (Office-Based Hepatology, Gastroenterology & Infectious Disease)
- Community Health Centers & Others
By Distribution Channel
- Specialty Pharmacies
- Hospital Pharmacies
- Retail & Online Pharmacies
By Region
- North America
- Europe
- Japan
- China
- Rest of Asia-Pacific
- Latin America
- Middle East & Africa
Contact Us:
Mr. Richard Johnson
Acumen Research and Consulting
India: +91 8983225533